{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T21:49:55Z","timestamp":1791409795893,"version":"4.3.3"},"reference-count":28,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100011989","name":"Gannan Normal University","doi-asserted-by":"publisher","award":["BSJJ202106"],"award-info":[{"award-number":["BSJJ202106"]}],"id":[{"id":"10.13039\/501100011989","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82360675"],"award-info":[{"award-number":["82360675"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004479","name":"Jiangxi Provincial Natural Science Foundation","doi-asserted-by":"publisher","award":["20242BAB20466"],"award-info":[{"award-number":["20242BAB20466"]}],"id":[{"id":"10.13039\/501100004479","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bioorganic Chemistry"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.bioorg.2026.110385","type":"journal-article","created":{"date-parts":[[2026,8,15]],"date-time":"2026-08-15T06:04:50Z","timestamp":1786773890000},"page":"110385","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Design, synthesis, and evaluation of aminopyrazolopyrimidopyridone derivatives as RETV804M and RETG810C inhibitors based on a \u201cchemical adaptation\u201d strategy"],"prefix":"10.1016","volume":"181","author":[{"given":"Jieman","family":"Lin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuyu","family":"Jia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianjun","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anzhi","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiaqing","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongdong","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meipin","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiayi","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bioorg.2026.110385_bb0005","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/0092-8674(85)90115-1","article-title":"Activation of a novel human transforming gene, ret, by DNA rearrangement","volume":"42","author":"Takahashi","year":"1985","journal-title":"Cell"},{"issue":"3","key":"10.1016\/j.bioorg.2026.110385_bb0010","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1038\/nm.2658","article-title":"RET, ROS1 and ALK fusions in lung cancer","volume":"18","author":"Takeuchi","year":"2012","journal-title":"Nat. Med."},{"issue":"4","key":"10.1016\/j.bioorg.2026.110385_bb0015","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1038\/sj.onc.1201199","article-title":"Oncogenic activation of RET by two distinct FMTC mutations affecting the tyrosine kinase domain","volume":"15","author":"Pasini","year":"1997","journal-title":"Oncogene"},{"issue":"8","key":"10.1016\/j.bioorg.2026.110385_bb0020","doi-asserted-by":"crossref","first-page":"1988","DOI":"10.1158\/1078-0432.CCR-16-1679","article-title":"RET aberrations in diverse cancers: next-generation sequencing of 4,871 patients","volume":"23","author":"Kato","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.bioorg.2026.110385_bb0025","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1210\/jc.2014-4153","article-title":"RET fusion as a novel driver of medullary thyroid carcinoma","volume":"100","author":"Grubbs","year":"2015","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.bioorg.2026.110385_bb0030","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1038\/nrendo.2016.11","article-title":"A comprehensive overview of the role of the RET proto-oncogene in thyroid carcinoma","volume":"12","author":"Romei","year":"2016","journal-title":"Nat. Rev. Endocrinol."},{"key":"10.1016\/j.bioorg.2026.110385_bb0035","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1038\/nrclinonc.2017.175","article-title":"Targeting RET-driven cancers: lessons from evolving preclinical and clinical landscapes","volume":"15","author":"Drilon","year":"2018","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.bioorg.2026.110385_bb0040","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.phrs.2017.12.021","article-title":"Role of RET protein-tyrosine kinase inhibitors in the treatment RET-driven thyroid and lung cancers","volume":"128","author":"Roskoski","year":"2018","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.bioorg.2026.110385_bb0045","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.jtho.2017.10.021","article-title":"Clinical and translational implications of RET rearrangements in non-small cell lung cancer","volume":"13","author":"Ferrara","year":"2018","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.bioorg.2026.110385_bb0050","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1200\/JCO.2016.70.9352","article-title":"Targeting RET in patients with RET-rearranged lung cancers: results from the global, multicenter RET registry","volume":"35","author":"Gautschi","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.bioorg.2026.110385_bb0055","doi-asserted-by":"crossref","first-page":"4346","DOI":"10.1021\/acs.jmedchem.3c02319","article-title":"Unraveling the promise of RET inhibitors in precision cancer therapy by targeting RET mutations","volume":"67","author":"Wang","year":"2024","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.110385_bb0060","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1200\/JCO.19.02551","article-title":"State-of-the-art strategies for targeting RET-dependent cancers","volume":"38","author":"Subbiah","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.bioorg.2026.110385_bb0065","doi-asserted-by":"crossref","first-page":"3504","DOI":"10.1111\/bph.14395","article-title":"Drug resistance profiles of mutations in the RET kinase domain","volume":"175","author":"Liu","year":"2018","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.bioorg.2026.110385_bb0070","doi-asserted-by":"crossref","first-page":"1869","DOI":"10.1093\/annonc\/mdy137","article-title":"Selective RET kinase inhibition for patients with RET-altered cancers","volume":"29","author":"Subbiah","year":"2018","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.bioorg.2026.110385_bb0075","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1158\/2159-8290.CD-18-0338","article-title":"Precision targeted therapy with BLU-667 for RETdriven cancers","volume":"8","author":"Subbiah","year":"2018","journal-title":"Cancer Discov."},{"key":"10.1016\/j.bioorg.2026.110385_bb0080","doi-asserted-by":"crossref","first-page":"6056","DOI":"10.1038\/sj.onc.1207810","article-title":"Disease associated mutations at valine 804 in the RET receptor tyrosine kinase confer resistance to selective kinase inhibitors","volume":"23","author":"Carlomagno","year":"2004","journal-title":"Oncogene"},{"key":"10.1016\/j.bioorg.2026.110385_bb0085","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/j.annonc.2020.10.599","article-title":"Structural basis of acquired resistance to selpercatinib and pralsetinib mediated by non-gatekeeper RET mutations","volume":"32","author":"Subbiah","year":"2021","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.bioorg.2026.110385_bb0090","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1016\/j.jtho.2020.01.006","article-title":"RET solvent front mutations mediate acquired resistance to selective RET inhibition in RET-driven malignancies","volume":"15","author":"Solomon","year":"2020","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.bioorg.2026.110385_bb0095","doi-asserted-by":"crossref","first-page":"1725","DOI":"10.1016\/j.annonc.2020.09.015","article-title":"Mechanisms of resistance to selective RET tyrosine kinase inhibitors in RET fusion-positive nonsmall-cell lung cancer","volume":"31","author":"Lin","year":"2020","journal-title":"Ann. Oncol."},{"issue":"15 suppl","key":"10.1016\/j.bioorg.2026.110385_bb0100","article-title":"The next-generation RET inhibitor TPX-0046 is active in drug-resistant and naive RET-driven cancer models","volume":"38","author":"Drilon","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.bioorg.2026.110385_bb0105","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1038\/s43018-023-00630-y","article-title":"Vepafestinib is a pharmacologically advanced RET-selective inhibitor with high CNS penetration and inhibitory activity against RET solvent front mutations","volume":"4","author":"Miyazaki","year":"2023","journal-title":"Nat. Cancer"},{"issue":"15 suppl","key":"10.1016\/j.bioorg.2026.110385_bb0110","article-title":"BOS172738, a highly potent and selective RET inhibitor, for the treatment of RET-altered tumors including RET-fusion + NSCLC and RET-mutant MTC: phase 1 study results","volume":"39","author":"Schoffski","year":"2021","journal-title":"J. Clin. Oncol."},{"issue":"16 suppl","key":"10.1016\/j.bioorg.2026.110385_bb0115","article-title":"The development of APS03118, a potent next-generation RET inhibitor for treating RET-inhibitor-resistant patients","volume":"40","author":"Subbiah","year":"2022","journal-title":"J. Clin. Oncol."},{"issue":"16 suppl","key":"10.1016\/j.bioorg.2026.110385_bb0120","article-title":"A first-in-human phase 1 study of the next-generation RET inhibitor, LOXO-260, in RET inhibitor refractory patients with RET-altered cancers (trial in progress)","volume":"40","author":"Pennell","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.bioorg.2026.110385_bb0125","doi-asserted-by":"crossref","first-page":"19736","DOI":"10.1021\/acs.jmedchem.4c02083","article-title":"Discovery and synthesis of heterobifunctional degraders of rearranged during transfection (RET) kinase","volume":"67","author":"Qiao","year":"2024","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.110385_bb0130","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1021\/acs.jmedchem.4c02692","article-title":"Discovery of an efficacious RET PROTAC degrader with enhanced antiproliferative activity against resistant cancer cells harboring RET solvent-front mutations","volume":"68","author":"Zhang","year":"2025","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.110385_bb0135","doi-asserted-by":"crossref","DOI":"10.1111\/cbdd.70039","article-title":"Structure-based design of 2-aminopyrazolpyrimidopyridone derivatives as new rearranged during transfection (RET) kinase inhibitors","volume":"105","author":"Shen","year":"2025","journal-title":"Chem. Biol. Drug Des."},{"key":"10.1016\/j.bioorg.2026.110385_bb0140","doi-asserted-by":"crossref","DOI":"10.1111\/cbdd.70039","article-title":"Design and synthesis of 2-aminopyrazolpyrimidopyridone derivatives as RETV804M and RETG810C kinase inhibitors","volume":"105","author":"Shen","year":"2025","journal-title":"Chem. Biol. Drug Des."}],"container-title":["Bioorganic Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0045206826009211?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0045206826009211?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T20:59:19Z","timestamp":1791406759000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0045206826009211"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":28,"alternative-id":["S0045206826009211"],"URL":"https:\/\/doi.org\/10.1016\/j.bioorg.2026.110385","relation":{},"ISSN":["0045-2068"],"issn-type":[{"value":"0045-2068","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Design, synthesis, and evaluation of aminopyrazolopyrimidopyridone derivatives as RETV804M and RETG810C inhibitors based on a \u201cchemical adaptation\u201d strategy","name":"articletitle","label":"Article Title"},{"value":"Bioorganic Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bioorg.2026.110385","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"110385"}}